Hereditary Testing Market Share, Size, Trends, Industry Analysis Report, By Disease Type (Hereditary Cancer Testing, Hereditary Non-Cancer Testing; By Technology (Cytogenetic, Biochemical, Molecular Testing); By Regions; Segment Forecast, 2020 - 2027

Report Summary

全球遗传测试市场价值USD 5.78 billion in 2019 and is expected to grow at a CAGR of 6.2% during the forecast period. A surge in the prevalence of hereditary diseases, awareness among the general population about the ill effects, innovations in genetic testing, and the emergence of rare diseases are the prime factors responsible for the market growth. Moreover, most of the players are focusing on women’s health inherited diseases and expanding their reach in the continuously evolving market space.

Furthermore, an increase in newborn screening increased the sales of genetic testing kits. In November 2019, the Virginia Department of General Services tested 7,868 infants for approximately 31 genetic and metabolic disorders. Thus, increased penetration of newborn screening further boosted the revenue for hereditary testing market.

Know more about this report:request for sample pages

Industry Dynamics

Growth Drivers
Reforms in the genetic test procedures have enabled the addition of multi-gene panels for hereditary cancers. National Comprehensive Cancer Network (NCCN) guidelines for ovarian, colorectal, and breast cancer offer information on the cancer risk factors, their management, and recommendations for the test panels. Recent developments in the distribution models are expected to benefit the hereditary disease testing market.

Technology providers play an important role in the industry by improving distribution services. Most of the companies are using cloud-based models to make bioinformatics expertise to all the stakeholders. For instance, as of March 2019, more than 14 licenses were issued for the Constellation software, used for non-invasive prenatal testing products and services. Although, hereditary genetic testing has huge advantages over traditional tests, still, experts believe test cost and data security concerns make worry consumers.

There are more than thirty million people in the U.S alone who suffer from the hereditary genetic disease, with patients being often misdiagnosed, sometimes long diagnosis timeline causes costly healthcare odyssey. RDI will leverage AI, ML, and NLP algorithms across huge datasets in the form of medical claims, genetic codes, WES data, and electronic health records to enable pharmaceutical companies to take informed critical decisions across drug commercialization, clinical trial planning, and drug development and discovery procedures. Thus, with such a dedicated approach towards genetic testing of hereditary diseases, expected to be fruitful in the forthcoming years.

Hereditary Testing Market Report Scope

The market is primarily segmented on the basis of disease type, technology, and region.

By Disease Type	By Technology	By Region
Hereditary Cancer Testing Lung Cancer Breast Cancer Colorectal Cancer Cervical Cancer Ovarian Cancer Prostate Cancer Stomach/Gastric Cancer Melanoma Sarcoma Uterine Cancer Pancreatic Cancer Others Hereditary Non-cancer Testing Genetic Tests Cardiac Diseases Rare Diseases Other Diseases Newborn Genetic Screening Preimplantation Genetic Diagnosis & Screening Non-invasive Prenatal Testing (NIPT) & Carrier Screening Tests	Cytogenetic Biochemical Molecular Testing	North America (U.S., Canada) Europe (France, Germany, UK, Italy, Spain, Netherlands, Austria) Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea) 拉丁美洲(巴西、墨西哥、基于“增大化现实”技术gentina) MEA (Saudi Arabia, UAE, Israel, South Africa)

Know more about this report:request for sample pages

Insight by Disease Type

Based on the disease type, the market is categorized into hereditary cancer testing and hereditary non-cancer testing. In 2019, the hereditary cancer testing segment is expected to dominate the market. The decline in the cost of cancer testing and the rising prevalence of different forms of cancer are key segment drivers. For instance, Color Genomics cancer screening product priced at around USD 259, whereas, products of Myriad, were priced at USD 4,000.

Low-cost substitutes for hereditary cancer testing have enabled the affordability of such products to the general population, particularly people suffering from breast, cervical, and lung cancer. BRCA1 carriers have an over 80% risk of inducing breast cancer. Cervical cancer caused by the Human Papilloma Virus (HPV) also drives the uptake of cancer testing products and services.

Geographic Overview

The market is bifurcated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). Europe accounted for the largest revenue share in 2019 and is expected to witness substantial growth over the forecast period. This can be attributed to a few factors such as key players operating in the region, government-sponsored treatments, favorable government policies to make genetic tests affordable for the general population.

North America is expected to account for a significant revenue share by the end of 2027 and the growth in the region is attributed to the several regulatory frameworks, high prevalence and awareness about the ill effects and economic burden of hereditary diseases, and commercial approval of the hereditary tests. As per the estimates of the National Institutes of Health (NIH), more than 30 million people in the U.S. are suffering from around 7,000 hereditary diseases. With the increase in the number of patients undergoing genome testing, rising income levels, is bound to support regional growth.

Competitive Insight

Key players operating in the global hereditary testing market include Myriad Genetics, Inc.; Natera, Inc.; F. Hoffmann-La Roche Ltd; Invitae Corporation; Illumina, Inc., Fulgent Genetic, Inc.; Quest Diagnostics Incorporated; Thermo Fisher Scientific, Inc.; Twist Bioscience; Agilent Technologies, Inc.; Sophia Genetics; Medgenome; and CENTOGENE N.V.